The estimated Net Worth of Jeffrey Jerome Ludwig is at least $5.09 Million dollars as of 17 July 2024. Mr Ludwig owns over 2,598 units of Puma Biotechnology Inc stock worth over $295,970 and over the last 5 years he sold PBYI stock worth over $185,559. In addition, he makes $4,609,635 as Chief Commercial Officer at Puma Biotechnology Inc.
Mr has made over 7 trades of the Puma Biotechnology Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,598 units of PBYI stock worth $9,613 on 17 July 2024.
The largest trade he's ever made was selling 12,956 units of Puma Biotechnology Inc stock on 3 January 2024 worth over $58,172. On average, Mr trades about 4,237 units every 77 days since 2020. As of 17 July 2024 he still owns at least 118,388 units of Puma Biotechnology Inc stock.
You can see the complete history of Mr Ludwig stock trades at the bottom of the page.
Jeffrey Jerome Ludwig is the Chief Commercial Officer at Puma Biotechnology Inc.
As the Chief Commercial Officer of Puma Biotechnology Inc, the total compensation of Mr Ludwig at Puma Biotechnology Inc is $4,609,635. There are 1 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.
Mr Ludwig is 55, he's been the Chief Commercial Officer of Puma Biotechnology Inc since . There are 8 older and 5 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.
Jeffrey's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES, CA, 90024.
Over the last 12 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo und Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Puma Biotechnology Inc executives and other stock owners filed with the SEC include: